ATHEALTERITY THERAPEUTICS LTD

Nasdaq alteritytherapeutics.com


$ 1.96 $ -0.05 (-2.55 %)    

Tuesday, 11-Jun-2024 11:28:41 EDT
QQQ $ 468.10 $ 3.19 (0.69 %)
DIA $ 388.08 $ -1.32 (-0.34 %)
SPY $ 537.01 $ 1.29 (0.24 %)
TLT $ 91.83 $ 0.94 (1.03 %)
GLD $ 214.15 $ 0.61 (0.29 %)
$ 1.91
$ 1.93
$ 1.91 x 100
$ 0.00 x 0
$ 1.93 - $ 1.96
$ 1.55 - $ 5.41
8,255
na
77.67M
$ 1.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alterity-therapeutics-phase-2-data-monitoring-committee-recommends-continuing-clinical-trial-as-planned-after-third-review

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-therapeutics-announced-presentation-of-new-data-demonstrating-potential-of-ath434-to-treat-rare-neurodegenerative-disease-friedreichs-ataxia

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing d...

 alterity-therapeutics-parkinsons-disease-and-multiple-system-atrophy-data-featured-at-the-american-academy-of-neurology-aan-2024-annual-meeting

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

 benchmark-reiterates-speculative-buy-on-alterity-therapeutics-maintains-4-price-target

Benchmark analyst Robert Wasserman reiterates Alterity Therapeutics (NASDAQ:ATHE) with a Speculative Buy and maintains $4 pr...

 alterity-therapeutics-earlier-announced-a-proposed-offering-of-285087720-shares

-ASX Announcement

 alterity-therapeutics-phase-2-data-monitoring-committee-recommends-continuing-clinical-trial-as-planned-after-second-review

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...

 alterity-therapeutics-highlights-successes-in-msa-research-and-plans-for-parkinsons-disease-trials-in-shareholder-letter

Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated...